Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Leptomeningeal Metastases
Phase PHASE1, PHASE2
Enrollment 34
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Leptomeningeal metastases (LM) is a lethal complication of malignant tumors, characterized by tumor cell invasion and proliferation within the subarachnoid space. LM from HER2-negative breast cancer remains challenging to treat, with a median overall survival of only 3-6 months despite aggressive therapy. This open-label, uncontrolled Phase I/II clinical study aims to evaluate the safety, feasibility, and potential efficacy of Sacituzumab Govitecan in combination with intrathecal pemetrexed chemotherapy for LM from HER2-negative breast cancer, with the objective of identifying a more effective treatment strategy.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Sacituzumab Govitecan — Patients receive Sacituzumab Govitecan 10mg/kg by intravenous infusion on days 1 and 8. Treatment cycles are every 21 days.
  • Drug: Pemetrexed — Intrathecal pemetrexed chemotherapy, administered via intracerebroventricular or lumbar puncture, consists of three phases: induction therapy (15 mg twice weekly for 2 weeks), consolidation therapy (once weekly for 4 consecutive weeks), and maintenance therapy (once monthly).

Primary Outcomes

  • Maximal tolerated dose (From the beginning of the treatment until two months after the treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-01-01
Completion: 2027-06-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 34 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guangzhou Medical University
Principal Investigators:
  • Zhenyu Pan (PRINCIPAL_INVESTIGATOR) - Huizhou Hospital of Guangzhou Medical University
Contact Information
Study Contact:
Zhenyu Pan
+8618718178286
dr-zypan@163.com
Guozi Yang
+8615804302755
guoziyang_1982@163.com
Zhenyu Pan, PhD,MD
+8618718178286
dr-zypan@163.com
The Affiliated Huizhou Hospital, Guangzhou Medical University
Interventions
  • Drug: Sacituzumab Govitecan — Patients receive Sacituzumab Govitecan 10mg/kg by intravenous infusion on days 1 and 8. Treatment cycles are every 21 days.
  • Drug: Pemetrexed — Intrathecal pemetrexed chemotherapy, administered via intracerebroventricular or lumbar puncture, consists of three phases: induction therapy (15 mg twice weekly for 2 weeks), consolidation therapy (once weekly for 4 consecutive weeks), and maintenance therapy (once monthly).
Study Locations (1 sites)
The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, Guangdong 516000 China
Eligibility Criteria
Inclusion Criteria: 1. A clear histopathologic diagnosis of breast cancer with HER2-negative subtype (including IHC 0, IHC 1+ or IHC 2+ and ISH negative); 2. Cerebrospinal fluid cytology confirms the presence of leptomeningeal metastases; or imaging findings combined with clinical symptoms and signs are consistent with the diagnosis of leptomeningeal metastases; 3. Age ≥ 18 years old. Exclusion Criteria: 1. Inadequate organ function: 1) Blood tests: ANC ≤ 1.5 x 10\^9/L, PLT ≤ 90 x 10\^9/L, Hb ≤ 90 g/L; 2) Blood biochemistry tests: TBIL ≥ 1.5 times the upper limit of normal; 3) ALT and AST ≥ 2.5 times the upper limit of normal; 2. Presence of serious and/or uncontrolled comorbidities that may affect participation: 1) Allergy to study drugs or adjuvant materials; 2) History of immunodeficiency (e.g., HIV-positive or other acquired or congenital immunodeficiency disease); 3) Severe concomitant diseases; 3. Pregnant and breastfeeding female patients; women of childbearing age who are unwilling or unable to use effective contraception; 4. Any other condition that, in the opinion of the investigator, makes the patient ineligible for participation in the study.
Conditions Mastectomy, Breast Neoplasm Malignant Pr...
Phase Not Applicable
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer, the most prevalent malignancy among women globally, is increasing in incidence. While non-metastatic breast cancer requires surgery, determining the optimal extent of resection remains challenging. Inadequate resection margins necessitate reoperation, leading to increased psychological stress, costs, and potentially compromised cosmetic outcomes and prognosis. Accurate preoperative assessment of resection extent is crucial and involves various factors, including imaging studies, physical examinations, tumor molecular subtypes, and intraductal carcinoma components. This prospective observational study aims to identify and integrate multiple predictive factors to enhance surgical planning and minimize reoperation rates in breast cancer patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No additional intervention — All patients are scheduled to undergo standard breast surgery as part of their routine clinical care. No additional interventions are administered specifically for this study.

Primary Outcomes

  • Concordance rate by the intraclass correlation coefficient Factors associated with discrepancies (Within 30 days after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-08-01
Completion: 2027-08-30
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Incheon St.Mary's Hospital
Collaborators: Yonsei University
Contact Information
Study Contact:
Young-Joon Kang, Ph.D.
82 32-280-5179
yjkang.md@gmail.com
Young-Joon Kang, MD, PhD
82-32-280-5179
yjkang.md@gmail.com
Incheon St. Mary's Hospital
Young-Joon Kang, MD, PhD
Incheon St. Mary's Hospital
Interventions
  • Other: No additional intervention — All patients are scheduled to undergo standard breast surgery as part of their routine clinical care. No additional interventions are administered specifically for this study.
Study Locations (1 sites)
Incheon St. Mary's Hospital, Incheon, South Korea
Eligibility Criteria
Inclusion Criteria: Adult patients (≥ 19 years old) diagnosed with breast cancer (invasive and in situ). Patients scheduled for surgical resection of the tumor Availability of both preoperative tumor size assessments and pathologic measurements post-surgery Exclusion Criteria: Patients with recurrent breast cancer Inflammatory breast cancer Patients who did not undergo surgery Patients whose preoperative tumor size data is not available or deficient for analyzing
Conditions Depression
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This technology development project will be informed and guided by initial data collection of human subject data. For this purpose, the investigators will recruit n=100 people with mild to moderate depression in a double-blinded, parallel-arm, sham-controlled data collection period administered at home and using the investigator's remotely supervised (RS) tDCS protocol. Enrolled participants will complete 10 days of 30-minute tDCS (2.0, DLPFC left anodal) using the RS-tDCS protocol. During each daily session, standard HR and impedance-based HR (i-HR), obtained from the tDCS headset, will be collected to identify a possible marker of response to tDCS in depression. Participants will be randomized 2:1 to active vs. sham tDCS.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Single Group Primary purpose: Other Masking/blinding: Double

Interventions / Regimen

  • Device: Active Transcranial Direct Current Stimulation (tDCS) — tDCS will be delivered using the 1x1 Mini CT tDCS device. For active tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout the session (29 minutes), and then ramp down (for 30 seconds) at the end. Participants will receive 10 sessions of tDCS over the course of this study on weekdays (M-F).
  • Device: Sham Transcranial Direct Current Stimulation (tDCS) — Sham tDCS will be delivered using the 1x1 Mini CT tDCS device. For sham tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 28 minutes, and then ramp up (for 30 seconds) and down (for 30 seconds) at the end. Participants will receive 10 sessions of sham tDCS over the course of this study on weekdays (M-F).

Primary Outcomes

  • Average Heart Rate (HR) Measured Using Polar H10 Chest Monitor (Up to Week 4)
  • Average HR Measured Using i-HR Data Logger (Up to Week 4)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-02
Completion: 2027-11-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Principal Investigators:
  • Giuseppina Pilloni, PhD (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Shayna Pehel
929-455-5104
Shayna.Pehel@nyulangone.org
Interventions
  • Device: Active Transcranial Direct Current Stimulation (tDCS) — tDCS will be delivered using the 1x1 Mini CT tDCS device. For active tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout the session (29 minutes), and then ramp down (for 30 seconds) at the end. Participants will receive 10 sessions of tDCS over the course of this study on weekdays (M-F).
  • Device: Sham Transcranial Direct Current Stimulation (tDCS) — Sham tDCS will be delivered using the 1x1 Mini CT tDCS device. For sham tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 28 minutes, and then ramp up (for 30 seconds) and down (for 30 seconds) at the end. Participants will receive 10 sessions of sham tDCS over the course of this study on weekdays (M-F).
Study Locations (1 sites)
NYU Langone Health, New York, New York 10017 United States
Eligibility Criteria
Inclusion Criteria: * Mild to moderate depression (Beck Depression Inventory(BDI)-II 14-28) * Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-V-TR) Depressive episode * Wide Range Achievement Test (WRAT)-4th Reading Recognition subtest standard score \>85 Exclusion Criteria: * Primary neurologic, psychiatric (e.g., multiple sclerosis, stroke, Parkinson's disease, spinal cord injury, intracranial mass, traumatic brain injury (TBI), epilepsy, mild cognitive impairment (MCI), or dementia), or major medical disorder (e.g., history of myocardial infarction, diabetes, thyroid disease, arrhythmia, atrial fibrillation) (medical history review) * DSM-V-TR bipolar depression, psychotic disorder, or alcohol or substance use disorder (M.I.N.I.) * Active or high suicidality risk (Columbia-Suicide Severity Rating Scale, C-SSRS), or otherwise judged as inappropriate by the study clinicians * History of a heart transplant, presence of permanent pacemaker implant or Left Ventricular Assist Device * Use of certain medications that can affect heart rate variability, such as beta-blockers, calcium channel blockers, or cardiac glycosides * Use of antidepressant, antipsychotic, anxiolytic, or stimulant medications * Pregnant or planning pregnancy during the study period * Seizure disorder or recent (\<5 years) seizure history * Presence of metal objects in the head/neck * Any skin disorder or skin sensitive area near stimulation locations
Conditions Type 1 Diabetes
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

More and more children and adolescents are using diabetes devices attached to the skin. The attachment of infusions sets to the skin provoke allergenic or toxic eczema, the continous infusion of insulin provoke subcutaneous changes and prolonged wear time seems to increase the risk of these complication. On the other site fewer skin stripping episodes with longer wear time and filtration of the insulin may be beneficial for the skin, therefore comparing the occurrence of subcutaneous hyper echogenicity, eczema and the skin barrier in users of 3 and 7 days infusions set is highly relevant. The primary aim of present study is to investigate if the use of three days insulin infusion set is superior to seven days in preventing the occurrence of hyperechogenicity in areas recently used for insulin infusion and if the type of insulin matter comparing insulin aspart - Novo Rapid, or insulin lispro - Humalog

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Mio Advanced infusions set — Insulin infusionsset fitting Medtronic 780 G insulin pump
  • Drug: Novorapid — Randomized to either Novorapid or Humalog
  • Device: Extended wear insulin infusion (EWIS) — Insulin infusionsset fitting Medtronic 780 G insulin pump
  • Drug: Humalog — Randomized to either Novorapid or Humalog

Primary Outcomes

  • Occurence of hyperchogenicity at last two positions for infusions sets (2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-20
Completion: 2026-12-31
Eligibility
Age: 7 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Steno Diabetes Center Copenhagen
Principal Investigators:
  • Jannet Svensson (PRINCIPAL_INVESTIGATOR) - Steno Diabetes Center Copenhagen
Contact Information
Study Contact:
Jannet Svensson, Professor
25488355
jannet.svensson@regionh.dk
Julian Bjerrekær, MD
24966836
julian.bjerrekaer@regionh.dk
Jannet Svensson
+4525488355
jannet.svensson@regionh.dk
Steno Diabetes Center Copenhagen
Interventions
  • Device: Mio Advanced infusions set — Insulin infusionsset fitting Medtronic 780 G insulin pump
  • Drug: Novorapid — Randomized to either Novorapid or Humalog
  • Device: Extended wear insulin infusion (EWIS) — Insulin infusionsset fitting Medtronic 780 G insulin pump
  • Drug: Humalog — Randomized to either Novorapid or Humalog
Study Locations (1 sites)
Steno Diabetes Center Copenhagen, Herlev, Capital 2730 Denmark
Eligibility Criteria
Inclusion Criteria: * Diagnosed with T1D * Diabetes duration of more than 6 months prior to inclusion. * Currently using the CE-marked hybrid closed-loop system - Medtronic 780G pump and the corresponding sensor with automated insulin delivery. * Planning to using the CE-marked hybrid closed-loop system - Medtronic 780G pump and the corresponding sensor with automated insulin delivery. * Being between 7 and 18 years of age prior to inclusion * Insulin needs per day above 8 units Exclusion Criteria: * Those who are unable to read and understand Danish * Those with impaired cognitive development that may interfere with the ability to answer questionnaires in Danish and/or be reached by phone or videocall
Conditions HER2-positive Metastatic Breast Cancer
Phase Not Applicable
Enrollment 200
Locations 37 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: CE-10-IVD — Leftover tumor tissue from a routine biopsy will be sent for analysis.

Primary Outcomes

  • Real-World Objective Response Rate (from date of first dose of T-DXd to date of last dose of T-DXd for each. Up to 100 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-10
Completion: 2029-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Abramson Cancer Center at Penn Medicine
Collaborators: Translational Breast Cancer Research Consortium, Danaher Inc.
Principal Investigators:
  • Angela DeMichele, MD (PRINCIPAL_INVESTIGATOR) - Abramson Cancer Center at Penn Medicine
Contact Information
Study Contact:
Angela DeMichele, MD
215-908-2599
angela.demichele@pennmedicine.upenn.edu
Emma Brophy
Emma.Brophy@ucsf.edu
University of California San Francisco Medical Center
Carl Brown
carl.brown@yale.edu
Smilow Cancer Hospital-Derby Care Center
Interventions
  • Diagnostic Test: CE-10-IVD — Leftover tumor tissue from a routine biopsy will be sent for analysis.
Study Locations (37 sites)
University of California San Francisco Medical Center, San Francisco, California 94143 United States
Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut 06418 United States
Smilow Cancer Hospital Care Center, Fairfield, Connecticut 06824 United States
Smilow Cancer Hospital at Glastonbury, Glastonbury, Connecticut 06033 United States
Smilow Cancer Hospital Care Center at Greenwich, Greenwich, Connecticut 06830 United States
Smilow Cancer Hospital Care Center, Guilford, Connecticut 06437 United States
Smilow Cancer Hospital at Saint Francis, Hartford, Connecticut 06105 United States
Yale-New Haven Hospital North Haven Medical Center, New Haven, Connecticut 06473 United States
Yale Cancer Center, New Haven, Connecticut 06511 United States
Smilow Cancer Hospital Care Center at Long Ridge, Stamford, Connecticut 06901 United States
Eligibility Criteria
Inclusion Criteria: * Women and men age \> 18 years * Metastatic breast cancer, histologically- confirmed. Any estrogen receptor (ER) status is allowed. ER status will be determined by local laboratory assessment utilizing ASCO/CAP guidelines. * Primary and/or metastatic tumor with 1+ level of expression of HER2 by immunohistochemistry as determined by local laboratory assessment utilizing ASCO/CAP guidelines. * Measurable disease by cross-sectional imaging at the start of treatment. Patients with measurable bone-only disease or active brain metastases are eligible. * Archival tissue available for biomarker assessment. One specimen should be the most recent metastatic biopsy. If HER2 1+ status was determined on a different specimen (either primary or metastatic tissue), that specimen is also required. Samples obtained from bone metastases that were processed via decalcification methods are not eligible. * Intention to initiate therapy with T-DXd (Enhertu) at FDA-approved dose and schedule as next line of therapy. If T-DXd was already initiated, patients must be registered within 30 days of initiation. * Ability to provide informed consent Exclusion Criteria: * Concurrent Her2-overexpressing metastatic breast cancer (as confirmed by a metastatic biopsy with IHC 3+ or IHC 2+ with FISH amplified as per standard ASCO/CAP guidelines)
Conditions Hypertension, Resistant to Conventional ...
Phase NA
Enrollment 120
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn weather the baroloop system is safe and works to treat hypertension in adults that do not respond sufficiently to medication. The main questions it aims to answer are: * Is the baroloop device associated with any major medical problems including death? * Does the baroloop lower the blood pressure of study participants? Participants will be implanted with the baroloop device. Afterwards they will visit the clinic after 14 days, 3 months, 6 months, 12 months, 18 months, and 24 months for adjustment of the device settings and/or other study related assessments. Participants will also be asked to answer questions regarding their quality of life.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: baroloop system — Participants will have the baroloop device implanted for selective stimulation of the vagus nerve.

Primary Outcomes

  • Safety of the baroloop device (6 months after initial stimulation)
  • Performance (6 months after initial stimulation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-22
Completion: 2031-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: neuroloop GmbH
Collaborators: Avania
Contact Information
Study Contact:
Medical Scientific Affairs
+49 761 1543390
study@neuroloop.de
Daria von Winzkowsky
winzkowsky@onkologie-muenster.de
Clemenshospital Münster
Olaf Oldenburg, Prof. Dr.
Clemenshospital Münster
Interventions
  • Device: baroloop system — Participants will have the baroloop device implanted for selective stimulation of the vagus nerve.
Study Locations (4 sites)
Clemenshospital Münster, Münster, North Rhine-Westphalia 48153 Germany
Marienhaus Klinikum Mainz, Mainz, Rhineland-Westphalia 55131 Germany
Städtisches Klinikum Dresden, Dresden, Saxony 01067 Germany
UMC Utrecht, Utrecht, Utrecht 3584 CX Netherlands
Eligibility Criteria
Inclusion Criteria: 1. Aged 18 years or older. 2. Persistent office systolic blood pressure (SBP) ≥ 140 mm Hg and diastolic blood pressure (DBP) \> 90 mm Hg on antihypertensive medicines on two visits separated by a minimum of four weeks. 3. Mean 24-hour systolic ABPM ≥ 130 mm Hg and mean 24 hour diastolic ABPM ≥ 80 mm Hg conducted after direct observed therapy to confirm that antihypertensive medicines were taken as prescribed during the ABPM measurement. 4. Stable drug regimen of 3 antihypertensive medicines consisting of a reninangiotensin blocker (ACE) or Angiotensin II Receptor Blocker (ARBs), a calcium channel blocker (CCB), and a diuretic for 4 weeks at treatment. 5. Willingness and ability to comply with follow-up requirements. 6. Signed informed consent. Exclusion Criteria: 1. Any patient in whom access to the vagal nerve is limited by the size of the vagus (a size not compatible with the baroloop cuff). 2. Any patient with a history of injury to the vagus nerve or its branches (e.g., the recurrent laryngeal nerve). 3. Secondary causes of hypertension. 4. Calculated eGFR \< 30 mL/min/1.73m2. 5. Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1c \> 10%). 6. Requirement for chronic oxygen therapy or mechanical ventilation. 7. Untreated (no CPAP therapy) sleep apnea (AHI \> 15) 8. Morbid obesity, defined as Body Mass Index \>40 kg/m2 or arm circumference 46 cm. 9. Pacemaker and/or implantable defibrillators. 10. History of transient ischemic accident or cerebrovascular accident during six (6) months prior to screening. 11. Symptomatic carotid artery disease or \> 70% occlusion of either carotid artery; any carotid malformation or lesion, a carotid bruit or other abnormal carotid sound. 12. Prior surgery, radiation therapy or scarring in the neck in the region of the carotid artery (e.g., patients with a tracheostomy, extensive thymectomy or thyroid surgery). 13. Limited mobility of the neck secondary to vertebral disease or prior vertebral surgery, including patients who wear a cervical support. 14. History of heart failure (NYHA class III-IV). 15. Cardiac arrythmias (atrial fibrillation, atrial flutter, etc.) that require anticoagulation if the condition interferes with a consistent measurement of blood pressure. 16. Unexplained syncope in the last 6 months. 17. History of bleeding disorders, thrombocytopenia, hemophilia, or significant anemia (hemoglobin (Hgb) \< 10 g/dl). 18. Current anticoagulation therapy (excluding antiplatelet therapy with aspirin as a sole therapy). 19. History of unresolved drug or alcohol use. 20. Active treatment of a psychiatric ailment. 21. Life expectancy of less than 12 months due to other disease. 22. Subject has a condition that, in the opinion of the investigator, precludes participation, including willingness to comply, with all follow-up procedures. 23. Participation in another clinical study for which follow-up is currently on-going. 24. Women who are pregnant 25. Resting heart rateof \< 45 beats/min s, confirmed at both baseline visits. 26. Baroreflex failure or autonomic neuropathy 27. Symptomatic, uncontrolled bradyarrhythmias 28. Atrioventricular block of any grade 29. Presence of a vagus stimulator 30. Patients who are likely to require magnetic resonance imaging (MRI) of the cervical area 31. Occupational exposure to high levels of non-ionizing radiation that may interfere with therapy 32. Patients with a limited ability to read, understand and execute adjustment procedures (for example, persons suffering from dementia). 33. Likely exposure to diathermy.
Conditions Breast Cancer
Phase NA
Enrollment 39
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The overall objective of this COBRE pilot project is to enhance the design of a 3-arm cluster randomized trial that will test the efficacy and mechanism of effect of the MyMammogram DA with or without a provider communication intervention. This will be accomplished through two aims: (1) Refine, with community partner input, a clinical trial protocol to optimize engagement among patients and primary care providers (PCPs) practicing in rural settings. In consultation with patients, PCPs, and informatics experts, the study team will refine site selection, randomization, patient and PCP recruitment, and data collection protocols to meet the needs of the rural health care delivery system and participants. The result of this aim will be a modified protocol and intervention strategy that is acceptable to partners. (2) Adapt and test trial and intervention implementation features to achieve protocol acceptance and adherence. The investigators will pilot the adapted three-arm randomized trial protocol in rural primary care settings that compares the MyMammogram DA with or without a risk summary provided to the PCP pre-visit, relative to usual care. Implementing the trial in two phases (n=15 each) will systematically identify barriers and facilitators to trial participation to refine protocols. Participants will receive acceptability surveys and investigators will conduct qualitative interviews with patients and PCPs to understand experiences with trial implementation from multiple perspectives.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: MyMammogram — An online breast cancer screening decision aid
  • Other: Provider communication — Provider will be provided with information from MyMammogram that includes patient's breast cancer risk and preferences for mammograms prior to the appointment

Primary Outcomes

  • Intervention acceptability (within one day of completing the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2027-01-20
Eligibility
Age: 39 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 39 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dartmouth-Hitchcock Medical Center
Collaborators: Trustees of Dartmouth College
Contact Information
Study Contact:
Christine M Gunn, PhD
603-646-5430
Christine.M.Gunn@dartmouth.edu
Christine Gunn, PhD
603-646-5430
Christine.M.Gunn@dartmouth.edu
Cheshire Medical Center
Christine Gunn
(603) 646-5430
christine.m.gunn@dartmouth.edu
New London Hospital Primary Care
Interventions
  • Behavioral: MyMammogram — An online breast cancer screening decision aid
  • Other: Provider communication — Provider will be provided with information from MyMammogram that includes patient's breast cancer risk and preferences for mammograms prior to the appointment
Study Locations (3 sites)
Cheshire Medical Center, Keene, New Hampshire 03431 United States
New London Hospital Primary Care, New London, New Hampshire 03257 United States
Newport Health Center, Newport, New Hampshire 03773 United States
Eligibility Criteria
Patient Inclusion Criteria: * Females * Aged 39-49 * Upcoming appointment with a participating primary care provider (within 4 weeks) * English or Spanish-speaking Patient Exclusion Criteria: * Personal history of breast cancer (including lobular carcinoma in situ and ductal carcinoma in situ or atypical hyperplasia) * Mammogram in the prior 9 months Clinician inclusion: Any practicing primary care provider at a participating site.
Conditions Major Depressive Disorder 1
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The present study aims to develop a culturally and methodologically adapted EMDR therapy protocol, determine its treatment fidelity, and then clinically test its efficacy in the treatment of Major Depressive Disorder in Pakistan by utilizing both in-person and online modalities of EMDR therapy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: EMDR Psychotherapy — EMDR psychotherapy will be delivered in person by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
  • Other: Online EMDR Psychotherapy — Online EMDR Psychotherapy will be delivered online by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.

Primary Outcomes

  • Major Depressive Disorder (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2025-09-30
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: true
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Khushal Khan Khattak Univeristy, Karak, Pakistan
Contact Information
Study Contact:
Anwar Khan
03245603231
akpashtoon1981@gmail.com
KKKUk
Interventions
  • Other: EMDR Psychotherapy — EMDR psychotherapy will be delivered in person by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
  • Other: Online EMDR Psychotherapy — Online EMDR Psychotherapy will be delivered online by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
Study Locations (1 sites)
KKKUk, Kohat, 27200 Pakistan
Eligibility Criteria
Inclusion Criteria: 1. The patient should exhibit symptoms of Major Depressive Disorder. 2. Male and female patients will be chosen equally. 3. Patients between the ages of 20 and 50 will be selected. 4. Patients should preferable be "treatment-naïve," meaning they have no recent history of any psychotherapy or medication. Exclusion Criteria: a. There must be no significant neuropsychological or cognitive disorders among the patients
Conditions Diabetic Peripheral Neuropathy, Diabetic...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In this study the effects of diabetic peripheral neuropathy will be assessed on balance control, balance recovery, and muscle electrical activity in adults over 50 years. Aim 1: Determine muscle activity and balance control during a sit-to-stand in adults age above 50 with and without diabetic peripheral neuropathy. Aim 2: Assess local balance recovery and latency responses to lateral surface perturbation during quiet standing.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: sit-to-stand — test for balance during movement from sitting to standing
  • Behavioral: stand to sit — test for balance during movement from standing to sitting
  • Behavioral: standing perturbation — test for balance recovery following perturbation
  • Other: MRI of sciatic nerve — measure of peripheral nerve diameter

Primary Outcomes

  • Center of pressure using force plate (First session (immediately after intervention))
  • Center of mass using Vicon cameras. (First session (immediately after intervention))
  • Joint moment using Nexus software (First session (immediately after intervention))
  • Local dynamic stability using Motek and Vicon system (First session (immediately after intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-12
Completion: 2028-08-31
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lisa Griffin
Contact Information
Study Contact:
Mohsen Alighanbari, M.Sc.
512-471-9228
m.alighanbari@utexas.edu
The University of Texas at Austin
Lisa Griffin, Ph.D.
5124712786
l.griffin@austin.utexas.edu
The University of Texas at Austin
Interventions
  • Behavioral: sit-to-stand — test for balance during movement from sitting to standing
  • Behavioral: stand to sit — test for balance during movement from standing to sitting
  • Behavioral: standing perturbation — test for balance recovery following perturbation
  • Other: MRI of sciatic nerve — measure of peripheral nerve diameter
Study Locations (1 sites)
The University of Texas at Austin, Austin, Texas 78712 United States
Eligibility Criteria
Inclusion Criteria: * Type II diabetes with peripheral neuropathy Exclusion Criteria: * Foot ulcer * Partial amputation * Have experience of Stroke * Painful neuropathy * Inability to stand or walk independently
Conditions Hormone Receptor-Positive Breast Cancer,...
Phase PHASE2
Enrollment 40
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolerability of tirzepatide, its feasibility based on discontinuation rates, and completion of treatment. Secondary objectives include evaluating 3-year invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), changes in BMI and body fat distribution, metabolic markers, and circulating tumor DNA (ctDNA).

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tirzepatide — The intervention aims to assess the feasibility, safety, and efficacy of tirzepatide for weight loss in patients with early-stage hormone receptor-positive, HER2-negative breast cancer, potentially improving treatment outcomes and overall health.

Primary Outcomes

  • Weight Loss Reduction with Tirzepatide during Adjuvant Treatment for HR+/Her2- Breast Cancer (Measured by Body Weight Reduction) (Through study completion, total of two years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-10-30
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rutgers, The State University of New Jersey
Collaborators: Ludwig Institute for Cancer Research
Principal Investigators:
  • Coral Omene, MD., PhD (PRINCIPAL_INVESTIGATOR) - Rutgers Cancer Institute
Contact Information
Study Contact:
Coral Omene, MD., PhD
732-235-3374
co273@cinj.rutgers.edu
Coral Omene, MD.,PhD
732-235-3374
co273@cinj.rutgers.edu
Trinitas Comprehensive Cancer Center
Coral Omene, MD.,PhD
732-235-3374
co273@cinj.rutgers.edu
RWJ Barnabas Health - Robert Wood Johnson University Hospital, Hamilton
Interventions
  • Drug: Tirzepatide — The intervention aims to assess the feasibility, safety, and efficacy of tirzepatide for weight loss in patients with early-stage hormone receptor-positive, HER2-negative breast cancer, potentially improving treatment outcomes and overall health.
Study Locations (7 sites)
Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey 07202 United States
RWJ Barnabas Health - Robert Wood Johnson University Hospital, Hamilton, Hamilton, New Jersey 08690 United States
RWJBarnabas Health - Cooperman Barnabas, Livingston, Livingston, New Jersey 07039 United States
RWJBarnabas Health - Monmouth Medical Center, Long Branch, New Jersey 07740 United States
Rutgers Cancer Institute, New Brunswick, New Jersey 08901 United States
RWJBarnabas Health - Newark Beth Israel Medical Center, Newark, New Jersey 07112 United States
RWJ Barnabas Health - Robert Wood Johnson University Hospital, Somerset, Somerville, New Jersey 08876 United States
Eligibility Criteria
Inclusion Criteria: * Consent: Be willing and able to provide written informed consent for the trial. * Age: Male or Female patients aged 18 years or older. * Breast Cancer Diagnosis: Have hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer previously diagnosed by biopsy. HR status is defined as estrogen receptor (ER) \>10% and/or progesterone receptor (PR) \>10%; HER2 status is defined as immunohistochemistry (IHC) 0 or 1+ or IHC 2+, fluorescence in situ hybridization (FISH) negative. * Stage: Have previously untreated early-stage, clinical or anatomic stage I, II, or III hormone receptor-positive breast cancer. * Definitive Treatment: Have had definitive treatment with curative intent for breast cancer, including surgery, chemotherapy, and radiotherapy as indicated. * Body Mass Index (BMI): Have a BMI of 30 kg/m² or more, or a BMI of 27 kg/m² or more with one weight-related complication (e.g., hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). * Performance Status: Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Cardiac Function: Have a left ventricular ejection fraction (LVEF) of 50% or greater, or greater than the institution's lower limit of normal (LLN), as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed at screening. * Organ Function: Demonstrate adequate organ function in screening labs. * Tumor Specimens: Have archived biopsy or surgical tumor specimens available as tumor blocks or unstained slides. Exclusion Criteria: * Other Clinical Studies: Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study. * Stage IV Breast Cancer: Have stage IV, metastatic breast cancer. * Cancer Type: Have HER2-positive or triple-negative breast cancer. * Active Malignancy: Have a concomitant active malignancy. * Performance Status: Have an Eastern Cooperative Oncology Group (ECOG) performance status greater than 2. * Body Mass Index: Have a BMI of less than 27 kg/m². * Type 1 Diabetes Mellitus: Have type 1 diabetes mellitus. * Gastric Emptying Abnormality: Have a known clinically important gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or chronically took drugs that directly affect gastrointestinal motility.
Conditions Peripheral Arterial Disease, Painful Dia...
Phase NA
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Peripheral arterial disease (PAD) affects over 230 million adults worldwide and is a highly morbid, costly, and disabling condition. Ischemic leg pain drives disability in PAD patients and results from oxygen supply-demand mismatch, autonomic dysfunction, and muscle breakdown. This leg pain, which is unresponsive to traditional pharmacotherapy, limits the patient's tolerance to exercise, which is an important disease-modifying intervention. Spinal cord stimulation is a well-established therapy for medically intractable pain, including painful diabetic neuropathy (PDN) and ischemic pain, but is not part of the standard-of-care for PAD despite limited promising clinical data. Early studies used first-generation, tonic stimulation devices, but with these it was impossible to perform sham-controlled trials to test the treatment. Since then, new types of waveform treatments, including high-frequency spinal cord stimulation (SCS), have been shown to be more effective in the treatment of intractable pain. While high-frequency SCS is approved for PDN treatment, it has never been tested in the treatment of claudication pain from PAD. This study will enroll up to 15 participants between the ages of 19 and 89 who have PAD and PDN and are successfully implanted with a permanent SCS. Twelve weeks after SCS implantation, participants will receive two weeks of stimulation and two weeks of sham intervention, in random starting order. Blood flow, blood pressure, skin oxygen levels, and participant reported pain int the lower extremities will be assessed before SCS implantation, 12 weeks after SCS implantation and during each of the treatment periods. Participants will also complete a quality of life survey at the same time points. Comparisons of these measurements with the baseline and post-implantation measurements to determine the effects of SCS.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Spinal cord stimulation — active spinal cord stimulation
  • Device: Sham stimulation — Sham stimulation

Primary Outcomes

  • High-frequency Spinal Cord Stimulation Effect on Analgesia (Baseline, 12 week follow-up after permanent spinal cord simulator, week 14 intervention #1 , week 16 intervention #2)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-18
Completion: 2027-07
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Nebraska
Collaborators: Nevro Corp
Principal Investigators:
  • Peter Pellegrino, MD (PRINCIPAL_INVESTIGATOR) - University of Nebraska
Contact Information
Study Contact:
Julia T Hoffman, MSN
402-552-3077
outcomesresearch@unmc.edu
Michael Lankhorst, MD
402-596-4200
michael.lankhorst@unmc.edu
University of Nebraska Medical Center
Interventions
  • Device: Spinal cord stimulation — active spinal cord stimulation
  • Device: Sham stimulation — Sham stimulation
Study Locations (1 sites)
University of Nebraska Medical Center, Omaha, Nebraska 68198 United States
Eligibility Criteria
Inclusion Criteria: * 19 years to 89 years old * Diagnosed diabetes mellitus * Signs or symptoms of neuropathy and maximum baseline visual-analog pain scale ≥ 5 cm and peripheral arterial disease (diagnosed by ankle-brachial index \< 0.90 or vascular imaging studies) with claudication and exertion-induced visual-analog pain scale ≥ 6 cm for a minimum of 3 months * Successful spinal cord stimulator (SCS) trial (\>50% relief of chronic lower extremity pain) and will have a new permanent SCS placed prior to study intervention Exclusion Criteria: * Uncontrolled psychological or psychiatric disorder * Inability to hold antithrombotic therapy per the American Society of Regional Anesthesia guidelines * Non-healing wounds * Gangrene * Critical limb ischemia * Prior lower extremity amputation * Inability to adhere to study follow-up * Mechanical spine instability based on flexion/extension radiographs of the lumbar spine * Prior or current spinal cord stimulator implant
Conditions Breast Cancer
Phase PHASE2
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Investigators plan to conduct a single-arm clinical study of adebelimab, a novel PD-L1 inhibitor, in the neoadjuvant treatment of early or locally advanced high-risk ER+/HER2- breast cancer, to explore whether the addition of immune checkpoint inhibitors to traditional neoadjuvant chemotherapy can improve the pathologic complete response rate (pCR) of patients, evaluate its therapeutic safety, and further analyze the biomarkers of the efficacy of neoadjuvant immunotherapy for ER+/HER2- breast cancer, so as to support the clinical application of the drug.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide — Adebrelimab 1200mg i.v. q3w combined with nab-paclitaxel 100mg/m2 qw\*12w followed by epirubicin 90mg/m2 and cyclophosphamide 600mg/m2 q3w for 4 cycles

Primary Outcomes

  • pCR rate (up to 8 months, after patients complete surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-11-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Jiao Tong University School of Medicine
Contact Information
Study Contact:
Haoyu Wang
86 021-64370045
meredithwhy@163.com
Xiaosong Chen
86 021-64370045
chenxiaosong0156@hotmail.com
Haoyu Wang
86 021-64370045
meredithwhy@163.com
Ruijin Hospital
Interventions
  • Drug: Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide — Adebrelimab 1200mg i.v. q3w combined with nab-paclitaxel 100mg/m2 qw\*12w followed by epirubicin 90mg/m2 and cyclophosphamide 600mg/m2 q3w for 4 cycles
Study Locations (1 sites)
Ruijin Hospital, Shanghai, Shanghai Municipality 200025 China
Eligibility Criteria
Inclusion Criteria: * pathologically diagnosed as unilateral primary invasive breast cancer with a) cT1c-T2N1-3 or cT3-4N0-3, b) Tumor Grade 3 or Grade 2 with PR- or Ki67 \&gt; 20%; * IHC ER expression ≥1%; IHC HER2 0 or 1+; IHC HER2 2+ and no amplification in FISH test; * At least one measurable lesion according to RECIST 1.1; * Available core needle biopsy samples for PD-L1 status testing; * ECOG 0 or 1 within 10 days prior to initiation of treatment; * Not currently pregnant or breastfeeding, agree to strict contraception during treatment and at least 6 months after last dose; * Intact hematologic, liver, renal and heart functions; * Signed written informed consent. Exclusion Criteria: * Bilateral invasive breast cancer or Stage IV breast cancer; * Severe heart disease; * Diagnosed as immune deficiency or receiving systemic steroid therapy or any form of immuno-suppressive therapy within 7 days prior to the first dose of treatment; * Had active autoimmune diseases requiring systemic therapy within the past 2 years; * Severe systemic infections or other serious medical conditions; * Other malignant tumors in the past 5 years, except for cured carcinoma in situ of the cervix and skin cancer without melanoma; * History of HIV infection; * Active HBV or HCV infection; * Known allergies or intolerance to the therapeutic drug or its excipients; * History of application of any immunotherapy targeting PD-1/PD-L1/T cell receptors; * Judged by the investigator to be unsuitable to participate in this study.